Scientific Advice - Protocol Assistance

Peter Embley appointed as
Chief Regulatory Officer.

Pete joins Arriello to lead it’s Regulatory Affairs team.

A focus on building up further expertise with new Principal Consultants, and our Clinical Regulatory Strategy and solutions.

Pete comes with over 24 years of experience working across the Pharmaceutical, CRO and Consulting Industries.

Grounded in UK and European regulatory activities, and in particular, developing and executing strategies for generic and early-stage development programs, his responsibilities have included, but not limited to; Agency Scientific Advice, feasibility of accelerated tools such as EMA-PRIME, MHRA-ILAP, CMC, PIP, Market-Access and MAA due-diligence.

More recently, Pete has supported US IND/EU CTA and Chinese IND submissions, leading a team for the development and execution of Early (& Post-Trial) Access Programs.

A keen advocate for professional regulatory development, Pete is a Fellow of the regulatory association (TOPRA), and a Module Leader on the TOPRA Regulatory Affairs MSc. course.  Pete is also a regular lecturer at the University of Limerick.

Pete will report to Arriello’s COO Anna Lukyanova.

Latest news.

View all
We are pleased to announce we will be in Amsterdam, The Netherlands, for the RAPS Euro Convergence 2023 from 10 to 12 May.
Events RAPS euro 2023
Sonia has 20 years of experience in global and local pharmacovigilance in both large pharma and service provider organizations.
Sonia Mangnoesing Promo
Our Chief Regulatory Officer Peter Embley will be speaking at the biotech focused Chief Medical Officer Summit 360 event in Boston April 3-4.
CMO summit 2023